Reviva Q1 net loss $6.6M; cash to fund ops through Q3 2023; Phase 3 topline data mid-2023

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss of $6.6M ($0.30/shr) vs $7.4M ($0.40) in Q1 2022; cash $11.3M at Mar 31, 2023, down from $18.5M.
Cash sufficient to fund current plans through Q3 2023; additional financing needed for Phase 2a studies.
Over 60% of ~400 patients enrolled in Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.
Brilaroxazine lipogel showed proof-of-concept in psoriatic mouse model; IND for psoriasis expected in 2024.
May initiate Phase 2a studies in bipolar, MDD, and ADHD in H2 2023 subject to additional financing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the first quarter ended March 31, 2023 results: net income approximately $6.6 million, EPS $0.30 per share.

Period: the first quarter ended March 31, 2023
Net income: approximately $6.6 million
EPS: $0.30 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $6.6 million, or $0.30 per share, for the three months ended March 31, 2023, compared to a net loss of approximately $7.4 million, or $0.40 per share, for the same period in 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-014572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.